Kidney cancer: The cytokine working group experience (1986–2001): Part II: Management of IL-2 toxicity and studies with other cytokines

By Dutcher Janice   Atkins Michael   Margolin Kim   Weiss Geoff   Clark Joseph   Sosman Jeff   Logan Theodore   Aronson Fred   Mier James  

Medical Oncology, Vol. 18, Iss. 3, 2001-09 ,pp. : 209-219

Humana Press, Inc

Access to resources Recommend Favorite

Phase II trial of interleukin 2, interferon , and 5-fluorouracil in metastatic renal cell cancer - a cytokine working group study.

By Dutcher J.   Logan T.   Gordon M.   Sosman J.   Weiss G.   Margolin K.   Plasse T.   Mier J.   Lotze M.   Clark J.   Atkins M.  

Urologic Oncology: Seminars and Original Investigations, Vol. 7, Iss. 2, 2002-03 ,pp. : 83-84

Elsevier

Access to resources Recommend Favorite

Quality control in multicentric clinical trials. An experience of the EORTC Gynecological Cancer Cooperative Group

By Favalli G.   Vermorken J.B.   Vantongelen K.   Renard J.   Van Oosterom A.T.   Pecorelli S.  

European Journal of Cancer, Vol. 36, Iss. 9, 2000-06 ,pp. : 1125-1133

Elsevier

Access to resources Recommend Favorite

Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination

By Romero Pedro   Cerottini Jean-Charles   Speiser Daniel  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 3, 2004-03 ,pp. : 249-255

Springer Publishing Company

Access to resources Recommend Favorite

Ethical and Design Issues of Phase I Clinical Trials in Cancer Patients

By Grunwald Hans W.  

Cancer Investigation, Vol. 25, Iss. 2, 2007-03 ,pp. : 124-126

Informa Healthcare

Access to resources Recommend Favorite